Innate Pharma (IPHA) EBIT (2019 - 2025)
Innate Pharma's (IPHA) quarterly EBIT came in at -$60.9 million in Q4 2025, down 6.59% YoY from -$65.2 million in Q4 2024, and down 111.5% on a QoQ basis from -$28.8 million in Q2 2025.
Innate Pharma (IPHA) EBIT (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of EBIT data on file, last reported at -$60.9 million in Q4 2025.
- Quarterly EBIT fell 6.59% year-over-year to -$60.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$175.1 million (down 82.4% YoY) and the FY2025 annual result came in at -$62.9 million, down 14.07% from the prior year.
- EBIT fell to -$60.9 million in Q4 2025, from -$28.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$433391.9 in Q2 2023 to a low of -$60.9 million in Q4 2025.
- A 5-year average of -$32.0 million and a median of -$28.8 million in 2025 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT jumped 69.36% — and 2024, when it tumbled 6438.23%.
- Tracing IPHA's EBIT over 5 years: stood at -$54.7 million in 2021, then jumped by 69.36% to -$16.8 million in 2022, then surged by 39.63% to -$10.1 million in 2023, then slumped by 464.39% to -$57.1 million in 2024, then retreated by 6.59% to -$60.9 million in 2025.
- The last three EBIT figures came in at -$60.9 million (Q4 2025), -$28.8 million (Q2 2025), and -$57.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 133.12 Mn |
| 10 | Innate Pharma | 204.27 Mn | 204.27 Mn | - | -60.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -60.88 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Dec 31, 2024 | -57.11 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Dec 31, 2023 | -10.12 Mn |
| Jun 30, 2023 | -433,391.91 |
| Dec 31, 2022 | -16.76 Mn |
| Dec 31, 2021 | -54.71 Mn |
| Jun 30, 2021 | -30.62 Mn |
| Dec 31, 2020 | -9.05 Mn |
| Jun 30, 2020 | -9.19 Mn |
| Dec 31, 2019 | -28.49 Mn |